新的药物组合显示,经林业发展局批准,在治疗转移性直肠癌方面,成功率达到60.9%。 New drug combo shows 60.9% success rate in treating metastatic colorectal cancer, FDA approved.

来自MD Anderson癌症中心的研究人员发现,将encorafenib、cetuximab和mFOLFOX6化疗相结合,可大大提高了受BRAF V600E突变影响的转移性直肠癌(mCRC)患者的回复率。 Researchers from MD Anderson Cancer Center found that a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy significantly improved response rates in patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutations. 第三阶段Bryakwater试验显示,总体答复率为60.9%,而标准治疗为40%。 The Phase III BREAKWATER trial showed a 60.9% overall response rate compared to 40% with standard treatments. 这种组合最近被FDA批准用于这一患者群. This combination was recently approved by the FDA for this patient group.